MX2017003370A - Composiciones, metodos y kits para el diagnostico de una neoplasia neuroendocrina gastroenteropancreatica. - Google Patents

Composiciones, metodos y kits para el diagnostico de una neoplasia neuroendocrina gastroenteropancreatica.

Info

Publication number
MX2017003370A
MX2017003370A MX2017003370A MX2017003370A MX2017003370A MX 2017003370 A MX2017003370 A MX 2017003370A MX 2017003370 A MX2017003370 A MX 2017003370A MX 2017003370 A MX2017003370 A MX 2017003370A MX 2017003370 A MX2017003370 A MX 2017003370A
Authority
MX
Mexico
Prior art keywords
gep
nen
methods
compositions
kits
Prior art date
Application number
MX2017003370A
Other languages
English (en)
Inventor
KIDD Mark
Mark Modlin Irvin
Drozdov Ignat
Original Assignee
Clifton Life Sciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clifton Life Sciences LLC filed Critical Clifton Life Sciences LLC
Publication of MX2017003370A publication Critical patent/MX2017003370A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/107—Nucleic acid detection characterized by the use of physical, structural and functional properties fluorescence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Se proveen métodos de diagnóstico, detección o pronóstico de una GEP-NEN, basa-dos en la puntuación del grado de expresión de biomarcadores que exhiben expresión diferencial en sujetos que tienen una GEP-NEN con respecto a una muestra de referencia o control; la invención también provee composiciones y klts que comprenden estos biomarcadores y métodos de uso de estos biomarcadores en subconjuntos o paneles de los mismos para diagnosticar, clasificar y monito-rear GEP-NEN y tipos de GEP-NEN; los métodos y composiciones aquí provistos se pueden usar para diagnosticar o clasificar a un sujeto que tiene una GEP-NEN, para distinguir entre diferentes etapas de GEP-NEN, por ejemplo, estable o progresiva, para proveer una medida del riesgo de desarrollar una GEP-NEN progresiva, y para evaluar la complenitud de los tratamientos de GEP-NEN que inclu-yen, sin limitación, cirugía y terapia con somatostatina.
MX2017003370A 2014-09-15 2015-09-15 Composiciones, metodos y kits para el diagnostico de una neoplasia neuroendocrina gastroenteropancreatica. MX2017003370A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462050465P 2014-09-15 2014-09-15
PCT/US2015/050274 WO2016044330A1 (en) 2014-09-15 2015-09-15 Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm

Publications (1)

Publication Number Publication Date
MX2017003370A true MX2017003370A (es) 2017-11-22

Family

ID=54207775

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017003370A MX2017003370A (es) 2014-09-15 2015-09-15 Composiciones, metodos y kits para el diagnostico de una neoplasia neuroendocrina gastroenteropancreatica.
MX2021012347A MX2021012347A (es) 2014-09-15 2017-03-14 Composiciones, metodos y kits para el diagnostico de una neoplasia neuroendocrina gastroenteropancreatica.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021012347A MX2021012347A (es) 2014-09-15 2017-03-14 Composiciones, metodos y kits para el diagnostico de una neoplasia neuroendocrina gastroenteropancreatica.

Country Status (13)

Country Link
US (3) US10407730B2 (es)
EP (2) EP3929303A1 (es)
JP (2) JP6782700B2 (es)
KR (1) KR20170045365A (es)
CN (1) CN107208132A (es)
AU (3) AU2015317893B2 (es)
CA (1) CA2959670C (es)
DK (1) DK3194618T3 (es)
ES (1) ES2881474T3 (es)
IL (2) IL250867B (es)
MX (2) MX2017003370A (es)
PL (1) PL3194618T3 (es)
WO (1) WO2016044330A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107208132A (zh) 2014-09-15 2017-09-26 克里夫顿生命科学有限责任公司 用于诊断胃肠胰神经内分泌瘤的组合物、方法和试剂盒
WO2018217627A1 (en) * 2017-05-25 2018-11-29 Liquid Biopsy Research LLC Methods for melanoma detection
AU2018375376A1 (en) * 2017-11-30 2020-05-14 Liquid Biopsy Research LLC Predicting peptide receptor radiotherapy using a gene expression assay
CN108048564B (zh) * 2018-02-09 2021-03-05 中国科学院昆明动物研究所 人glt8d1基因的新用途
US11948296B2 (en) * 2018-07-30 2024-04-02 Agency For Science, Technology And Research Method and system for assessing fibrosis in a tissue sample
AU2020363786A1 (en) 2019-10-10 2022-05-12 Liquid Biopsy Research LLC Compositions, methods and kits for biological sample and RNA stabilization
FR3110764B1 (fr) * 2020-05-20 2024-05-10 Quantum Surgical Méthode de prédiction de la récidive d’une lésion par analyse d’images
CN113215255B (zh) * 2021-04-26 2022-04-05 山东天川精准医疗科技有限公司 用于肝癌早期诊断或预后的生物标记物及其用途
WO2024015968A2 (en) * 2022-07-15 2024-01-18 Emendobio Inc. Strategies for knock-ins at aplp2 safe harbor sites
WO2024073652A1 (en) * 2022-09-30 2024-04-04 Liquid Biopsy Research LLC Methods for neuroendocrine cancer detection in saliva

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005020795A2 (en) * 2003-08-25 2005-03-10 The Johns Hopkins University Method of diagnosis and treatment of pancreatic endocrine neoplasms based on differntial gene expression analysis
KR101642363B1 (ko) 2008-06-12 2016-07-25 입센 바이오이노베이션 리미티드 신경내분비계 질환의 억제
DK2681333T3 (en) * 2011-03-01 2018-01-08 Univ Yale EVALUATION OF RESPONSE TO GASTROENTEROPANCREATIC NEUROENDOCRINE NEOPLASIS (GEP-NENE) THERAPY
CN107208132A (zh) 2014-09-15 2017-09-26 克里夫顿生命科学有限责任公司 用于诊断胃肠胰神经内分泌瘤的组合物、方法和试剂盒

Also Published As

Publication number Publication date
US20220325351A1 (en) 2022-10-13
AU2015317893A1 (en) 2017-03-23
KR20170045365A (ko) 2017-04-26
DK3194618T3 (da) 2021-07-12
AU2015317893B2 (en) 2021-05-20
US20190345568A1 (en) 2019-11-14
PL3194618T3 (pl) 2021-12-13
IL250867B (en) 2021-03-25
CN107208132A (zh) 2017-09-26
JP2021019618A (ja) 2021-02-18
CA2959670C (en) 2024-02-20
IL250867A0 (en) 2017-04-30
BR112017005279A2 (pt) 2017-12-12
CA2959670A1 (en) 2016-03-24
EP3194618B1 (en) 2021-04-21
EP3194618A1 (en) 2017-07-26
AU2021212151B2 (en) 2023-08-03
ES2881474T3 (es) 2021-11-29
AU2023258444A1 (en) 2023-11-23
JP6782700B2 (ja) 2020-11-11
EP3929303A1 (en) 2021-12-29
JP7157788B2 (ja) 2022-10-20
US10407730B2 (en) 2019-09-10
AU2021212151A1 (en) 2021-08-26
US11168372B2 (en) 2021-11-09
WO2016044330A1 (en) 2016-03-24
IL281355A (en) 2021-04-29
JP2017528164A (ja) 2017-09-28
US20160076106A1 (en) 2016-03-17
IL281355B (en) 2022-02-01
MX2021012347A (es) 2021-10-22

Similar Documents

Publication Publication Date Title
MX2021012347A (es) Composiciones, metodos y kits para el diagnostico de una neoplasia neuroendocrina gastroenteropancreatica.
BR112019004075A2 (pt) métodos para diagnosticar um indivíduo com suspeita de endometriose, para detectar mirna, para diagnosticar um indivíduo que apresenta sintomas de endometriose ou com suspeita de endometriose, para tratar um indivíduo com endometriose, para diagnosticar e tratar um indivíduo com suspeita de endometriose, para diagnosticar endometriose em um indivíduo, para diagnosticar ou prover um prognóstico para endometriose em um indivíduo e para monitorar uma resposta a um tratamento de endometriose em um indivíduo, e, kit.
MX367046B (es) Marcadores especificos de via para diagnosticar sindrome del intestino irritable.
EP3839510A3 (en) Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
MX2017008421A (es) Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga.
EP4242329A3 (en) Use of markers including filamin a in the diagnosis and treatment of prostate cancer
MX2018008421A (es) Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
MX2018009304A (es) Metodos de diagnostico y pronostico para episodios y enfermedades cardiovasculares.
WO2016044338A3 (en) Methods and systems for diagnosing sleep disorders
WO2015094996A3 (en) Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists
MX2015012303A (es) Un metodo no invasivo para medir el estres oxidativoy daño oxidativo de los biomarcadores cutaneos.
MX2016012285A (es) Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
MX2019008260A (es) Metodos y composiciones para la evaluacion y tratamiento de lesion renal e insuficiencia renal con base en la medicion del ligando 14 de quimiocina de la porcion c-c.
WO2014004889A3 (en) Plasma analytes predict diagnosis and prognosis of thoracic aortic aneurysm
NZ729773A (en) Biomarkers for disease progression in melanoma
IN2014DE01077A (es)
IN2014DN08537A (es)
MX2017005126A (es) Metodos y composiciones para el diagnostico y pronostico de lesion renal e insuficiencia renal.
GB2552271A (en) A method for diagnosing lung cancer
CA3056911A1 (en) Methods for diagnosing and treating inflammatory bowel disease
GB2565740A (en) Analysis of bodily fluids using infrared spectroscopy for the diagnosis and/or prognosis of cancer
MX2016009490A (es) Ensayo novedoso para detectar periostina humana.
WO2018085363A3 (en) Cd147 detection in diagnostic, prognostic and monitoring methods for multiple myeloma
MX2018011679A (es) Biomarcadores de proteopatias y usos de los mismos.
EP3502271A3 (en) Blood biomarkers for appendicitis and diagnostics methods using biomarkers